Press release
Investigation announced for Investors in NASDAQ: MRTX shares over possible Violations of Securities Laws by Mirati Therapeutics, Inc.
An investigation for investors in Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares over potential securities laws violations.
Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Mirati Therapeutics, Inc. (NASDAQ: MRTX) concerning whether a series of statements by Mirati Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
San Diego, CA based Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. Mirati Therapeutics, Inc. reported that its annual Total Revenue rose from $3.33 million in 2019 to $13.39 million in 2020, and that its Net Loss increased from $212.25 million in 2019 to $357.93 million in 2020.
On November 1, 2021, Mirati Therapeutics, Inc., in an SEC filing, disclosed that certain executives would no longer be serving in their positions. In the filing, the Company stated, “
On October 28, 2021, it was determined that Daniel R. Faga would cease serving as the Executive Vice President, Chief Operating Officer and principal financial officer of Mirati Therapeutics, Inc. (the “Company”) and that Joseph Leveque would cease serving as the Company’s Executive Vice President and Chief Medical Officer, effective as of November 1, 2021.”
Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) declined from $195.99 per share on October 25, 2021, to $157.00 per share on November 3, 2021.
Those who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in NASDAQ: MRTX shares over possible Violations of Securities Laws by Mirati Therapeutics, Inc. here
News-ID: 2452803 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Mirati
Neurofibrosarcoma Market Is Expected to Expand at a Healthy Growth Rate During t …
DelveInsight's "Neurofibrosarcoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neurofibrosarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
[https://www.delveinsight.com/report-store/neurofibrosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size…
Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Development and Compa …
DelveInsight's, "Colorectal Cancer Pipeline Insight" report provides comprehensive insights about 145+ companies and 150+ pipeline drugs in the Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Colorectal…
Metastatic Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Developmen …
DelveInsight's, "Metastatic Colorectal Cancer Pipeline Insight 2023" report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Histone Deacetylase Inhibitors Market 2023 | Futuristic Trends- Onxeo, Acetylon …
The Histone Deacetylase Inhibitors research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Histone Deacetylase Inhibitors research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving force.
Download FREE Sample Report…
Investigation announced for Long-Term Investors in shares of Mirati Therapeutics …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Mirati Therapeutics, Inc.
Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Mirati Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San…
Investigation announced for NASDAQ: MRTX Investors over possible Wrongdoing at M …
Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Mirati Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based Mirati…
